Product Description
| Chemical Name | Ethyl (2E)-4-Oxo-2-butenoate |
Synonyms | Ethyl fumaraldehydate; |
CAS No. | 2960-66-9 |
Refractive index | 1.4550 |
Water | NMT0.3% |
Assay | NLT96.0% |
Appearance | Colorless to little yellow liquid |
Facilities | with advanced synthetic and analytical equipments, we can ensure a high quality of the product. |
Supplemental Information | This is classified as a Dangerous Good for transport and may be subject to additional shipping charges. |
Application | It can react with benzenesulfonamide to produce N-(Phenylsulfonyl)-(4-ethoxycarbonyl)-1-aza-1,3-butadiene. This reaction will need reagent TiCl4, and the menstruum CH2Cl2. The reaction time is 8 hours with temperature of 0°C, and the yield is about 60%. |
Store | Be kept airtight, dry and in cool place. |
Packing | 25kg/barrel, 200kgs/barrel or as customer’s request, always with photo before shipment |
Shipping
We can export from many China main ports, convenient for the customers provide logistics services.
FAQ
Q: Can I have a sample order?
Yes, we welcome sample order to test and check quality. Mixed samples are acceptable.
Q: What are your payment and trade terms?
Payment term: TT, L/C at sight , DP, D/A
Trade terms :FOB China, CFR, CIF
Q: What is the lead time?
Samples need 1 working days, mass products need 7 days.
Q: How do you ship the goods and how long does it take arrive?
We usually ship by DHL, UPS, FedEx or TNT for sample. Air and sea ship is acceptable. It usually needs 7 days to arrive except sea ship.
Q：How about the product usage ?
Ethyl (2E) -4-Oxo-2-butenoate is one of the important intermediates in the treatment of osteoporosis with minophosphonic acid. Osteoporosis is a bone disease characterized by low bone mass and structural degradation of bone tissue. Osteoporosis treatments currently used clinically, such as estrogen, selective estrogen modulators, calcitonin, and bisphosphonates, are mainly beneficial for reducing bone resorption; there are also some treatments such as fluoride and Parathyroid hormone can increase bone formation. Anti-bone resorption therapy is very effective in treating osteoporosis, even though it usually does not induce the formation of new bone. For Ethyl (2E) -4-Oxo-2-butenoate, the research and development of minophosphonic acid will provide a safer, effective and convenient treatment for patients with diseases.
